Cutaneous Scrotal Metastasis Secondary to Primary Prostate Adenocarcinoma Responding to Immunotherapy

This case demonstrates the aggressive progression of prostate adenocarcinoma, failing 3 treatment regimens. Although the patient initially responded to treatments, he developed cutaneous metastasis. Genomic tumor analysis of scrotal tissue confirmed targetable molecular mutations. Treatment with sys...

Full description

Saved in:
Bibliographic Details
Main Authors: Celine A. Fadel, Andre M. Kallab
Format: Article
Language:English
Published: American College of Physicians 2022-12-01
Series:Annals of Internal Medicine: Clinical Cases
Online Access:https://www.acpjournals.org/doi/10.7326/aimcc.2022.0682
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850202443719114752
author Celine A. Fadel
Andre M. Kallab
author_facet Celine A. Fadel
Andre M. Kallab
author_sort Celine A. Fadel
collection DOAJ
description This case demonstrates the aggressive progression of prostate adenocarcinoma, failing 3 treatment regimens. Although the patient initially responded to treatments, he developed cutaneous metastasis. Genomic tumor analysis of scrotal tissue confirmed targetable molecular mutations. Treatment with systemic immunotherapy was initiated with complete resolution of disease. This case reveals the rare metastasis of prostate adenocarcinoma to the scrotum with advanced refractory cancer and the successful response to immunotherapy. It illustrates the importance of tumor genomic testing in advanced refractory prostate cancer.
format Article
id doaj-art-3eecec1025914e2ca74f8bc0d998ea3b
institution OA Journals
issn 2767-7664
language English
publishDate 2022-12-01
publisher American College of Physicians
record_format Article
series Annals of Internal Medicine: Clinical Cases
spelling doaj-art-3eecec1025914e2ca74f8bc0d998ea3b2025-08-20T02:11:46ZengAmerican College of PhysiciansAnnals of Internal Medicine: Clinical Cases2767-76642022-12-0111010.7326/aimcc.2022.0682Cutaneous Scrotal Metastasis Secondary to Primary Prostate Adenocarcinoma Responding to ImmunotherapyCeline A. Fadel0Andre M. Kallab11Internal Medicine Residency: Northeast Georgia Medical Center, Gainesville, Georgia2Department of Hematology-Oncology: Northeast Georgia Diagnostic Clinic, Gainesville, GeorgiaThis case demonstrates the aggressive progression of prostate adenocarcinoma, failing 3 treatment regimens. Although the patient initially responded to treatments, he developed cutaneous metastasis. Genomic tumor analysis of scrotal tissue confirmed targetable molecular mutations. Treatment with systemic immunotherapy was initiated with complete resolution of disease. This case reveals the rare metastasis of prostate adenocarcinoma to the scrotum with advanced refractory cancer and the successful response to immunotherapy. It illustrates the importance of tumor genomic testing in advanced refractory prostate cancer.https://www.acpjournals.org/doi/10.7326/aimcc.2022.0682
spellingShingle Celine A. Fadel
Andre M. Kallab
Cutaneous Scrotal Metastasis Secondary to Primary Prostate Adenocarcinoma Responding to Immunotherapy
Annals of Internal Medicine: Clinical Cases
title Cutaneous Scrotal Metastasis Secondary to Primary Prostate Adenocarcinoma Responding to Immunotherapy
title_full Cutaneous Scrotal Metastasis Secondary to Primary Prostate Adenocarcinoma Responding to Immunotherapy
title_fullStr Cutaneous Scrotal Metastasis Secondary to Primary Prostate Adenocarcinoma Responding to Immunotherapy
title_full_unstemmed Cutaneous Scrotal Metastasis Secondary to Primary Prostate Adenocarcinoma Responding to Immunotherapy
title_short Cutaneous Scrotal Metastasis Secondary to Primary Prostate Adenocarcinoma Responding to Immunotherapy
title_sort cutaneous scrotal metastasis secondary to primary prostate adenocarcinoma responding to immunotherapy
url https://www.acpjournals.org/doi/10.7326/aimcc.2022.0682
work_keys_str_mv AT celineafadel cutaneousscrotalmetastasissecondarytoprimaryprostateadenocarcinomarespondingtoimmunotherapy
AT andremkallab cutaneousscrotalmetastasissecondarytoprimaryprostateadenocarcinomarespondingtoimmunotherapy